A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma

Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs BLU 554 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 12 Sep 2017 Results (Cut-off date: 20 Apr 17; n=61) presented at the 42nd European Society for Medical Oncology Congress
    • 10 Sep 2017 According to a Blueprint Medicines media release, updated data from the study (data cut-off August 18, 2017) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 10 Sep 2017 According to a Blueprint Medicines media release, Company plans to initiate an additional cohort in this clinical trial in the first quarter of 2018 to evaluate BLU-554 in TKI-naive patients with FGFR4-driven hepatocellular carcinoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top